CYP3A4
HGNC ↗5 article(s) in the watch · Pharmacogenomics
CYP3A4 is the cytochrome P450 enzyme most involved in drug metabolism. The reduced-function CYP3A4*22 allele influences exposure to many substrates (statins, tacrolimus, calcium-channel blockers…); interpretation must account for frequent drug-drug interactions.
Drugs involved: many substrates (immunosuppressants, statins, calcium-channel blockers)
Recommendation: No dedicated CPIC guideline
Curated publications
Side effects in hypertension treatment: a pharmacogenomic analysis
Antihypertensive drug side effects
Application of Virtual Twin PBPK Models in Individuals with Obesity via CYP3A4 Phenotyping Using Endogenous Biomarker Data
Personalized dosing in obese patients — *CYP3A4* phenotyping
Opioid Toxicity Following Concomitant Use of Macrolide Antibiotics with Fentanyl, Hydromorphone, or Oxycodone: A Population-Based Study.
Opioid toxicity from CYP3A4 drug-drug interaction
How Drug-Drug Interaction Studies Inform Drug Labeling: A Survey of US FDA-Approved New Molecular Entities from 1998 to 2022.
Drug-drug interactions / FDA labeling
A Physiologically Based Pharmacokinetic Model to Predict Potential Drug-Drug Interactions of TPN171, a Novel Phosphodiesterase Type 5 Inhibitor.
PAH / erectile dysfunction — TPN171 drug interactions
Frequently asked questions
Which drugs are affected by CYP3A4 in pharmacogenomics?+
many substrates (immunosuppressants, statins, calcium-channel blockers) — No dedicated CPIC guideline
How many Geno'X publications cover the CYP3A4 gene?+
5 publication(s) on CYP3A4 have been selected, summarised and scored by Geno'X on a public grading grid (domains: Pharmacogenomics).
